Eli Lilly Gets CHMP Backing of Jaypirca in Chronic Lymphocytic Leukemia

Dow Jones
02-28
 

By Colin Kellaher

 

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic leukemia.

Eli Lilly on Friday said the recommendation covers Jaypirca for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a Bruton's tyrosine kinase inhibitor.

The Indianapolis drugmaker said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the next one to two months.

Eli Lilly previously won conditional European approval for Jaypirca in adults with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

February 28, 2025 08:59 ET (13:59 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10